RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers

EDINBURGH, Scotland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 8, 2026--